Inoviq LtdASX: IIQ

IIQ Licences worldwide OC Biomarker IP from UniQuest

· Issued by Inoviq Ltd

Filed with ASX · · 2 pages · English

Summary by 6ix AI

This licence supports the development of Inoviq's EXO-OC test for early detection of ovarian cancer in asymptomatic women. The company is in discussions with clinical laboratories to accelerate the launch of the test in the US. The licensed intellectual property includes patent applications for novel biomarker combinations and methods for the ovarian cancer test. Inoviq plans to commercialise the EXO-OC test as a Laboratory Developed Test in the US before expanding globally.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Inoviq Ltd on 6ix

Earlier from Inoviq

Later from Inoviq

All Inoviq news releases